首页> 外文期刊>EFSA Journal >Safety evaluation of steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts
【24h】

Safety evaluation of steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts

机译:通过高度纯化的甜菊糖苷和/或莱佛士叶提取物的酶促生物转化获得的甜菊糖糖苷制剂的安全性评价,包括Rebaudioside Am。

获取原文
           

摘要

The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion on the safety of steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts. These steviol glycoside preparations are produced via enzymatic bioconversion of highly purified stevioside and/or rebaudioside A extracts obtained from stevia plant using two UDP-glucosyltransferases and one sucrose synthase enzymes produced by the genetically modified strains of E. coli K-12 that facilitate the transfer of glucose to purified stevia leaf extracts via glycosidic bonds. The Panel considered that the parental strain is a derivative of E. coli K-12 which is well characterised and its safety has been documented; therefore, it is considered to be safe for production purposes. The Panel concluded that there is no safety concern for steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts using UDP-glucosyltransferases and sucrose synthase enzymes produced by the genetically modified strains of E. coli K-12, to be used as a food additive. The Panel recommends the European Commission to consider the proposal of establishing separate specifications for steviol glycoside preparations, including rebaudioside AM, obtained by enzymatic bioconversion of highly purified stevioside and/or rebaudioside A stevia leaf extracts in Commission Regulation (EU) No 231/2012.
机译:食品添加剂和调味料(FAF)的EFSA小组(FAF)对甜菊糖苷醇类制剂的安全性提供了科学意见,包括高度纯化的甜菊甙和/或莱佛亚叶子提取物的酶促生物转化。这些Steviol糖苷制剂通过高度纯化的甜菊糖苷和/或从甜叶菊植物获得的提取物,使用两种UDP-葡糖基转移酶和通过促进转移的转基因的遗传修饰的菌株产生的一种蔗糖合成酶和一种蔗糖合成酶而产生的酶促生物转化。葡萄糖通过糖苷键纯化甜叶菊叶提取物。该小组认为亲本菌株是大肠杆菌K-12的衍生物,其特征很好,并记录了其安全性;因此,它被认为是安全的生产目的。该小组得出结论,甜菊醇糖苷的制剂没有安全担心,包括培养的甜菊糖甙和/或莱佛斯叶片用UDP-葡糖基转移酶和由遗传修饰的e的遗传改性菌株产生的蔗糖合成酶和蔗糖合成酶获得的培养基糖苷的制剂。 。COLI K-12,用作食品添加剂。该小组建议欧洲委员会考虑通过高度纯化的甜菊甙和/或Rebaudioside在委员会条例(欧盟)的蛋白质(欧盟)No 231/2012中的酶促生物转化,包括莱佛士糖苷am,包括Rebaudioside AM的甜菊糖甙制剂的单独规范的提案。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号